Brown M, Rivier J, Vale W
Endocrinology. 1979 Jun;104(6):1709-15. doi: 10.1210/endo-104-6-1709.
Somatostatin (SRIF) has been tested for its actions on the central nervous system to affect glucoregulation. In doses ineffective when given systemically , SRIF and SRIF analogs given intracisternally (ic) reduce hyperglycemia and hyperglucagonemia after ic bombesin administration. The SRIF analog, des-AA1, 2, 4, 5, 12, 13-[D-Trp8]SRIF, decreases plasma insulin and elevates plasma glucose and glucagon when given systemically. However, when given ic, this peptide prevents the rise in glucose and glucagon after ic bombesin administration and is 10 times more potent than SRIF in reducing bombesin-induced hyperglycemia. Other analogs of SRIF and various unrelated peptides were found to be ineffective in reducing bombesin-induced hyperglycemia. des-AA1, 2, 4, 5, 12, 13-[D-Trp]SRIF prevented the hyperglycemia induced by surgical stress or by ic administration of beta-endorphin or carbacol. des-AA1, 2, 4, 5, 12, 13-[D-Trp]SRIF given ic did not prevent hyperglycemia induced by systemic administration of epinephrine, arginine, or glucagon. These studies suggest that SRIF and its analogs may act within the brain to affect glucoregulation.
生长抑素（SRIF）已被测试其对中枢神经系统影响糖调节的作用。当全身给药无效时，脑池内（ic）给予SRIF及其类似物可降低脑池内注射蛙皮素后的高血糖和高胰高血糖素血症。SRIF类似物des-AA1, 2, 4, 5, 12, 13-[D-Trp8]SRIF全身给药时会降低血浆胰岛素水平，升高血浆葡萄糖和胰高血糖素水平。然而，脑池内给药时，该肽可预防脑池内注射蛙皮素后葡萄糖和胰高血糖素的升高，且在降低蛙皮素诱导的高血糖方面比SRIF强10倍。发现SRIF的其他类似物和各种不相关的肽在降低蛙皮素诱导的高血糖方面无效。des-AA1, 2, 4, 5, 12, 13-[D-Trp]SRIF可预防手术应激或脑池内注射β-内啡肽或卡巴胆碱诱导的高血糖。脑池内给予des-AA1, 2, 4, 5, 12, 13-[D-Trp]SRIF不能预防全身给予肾上腺素、精氨酸或胰高血糖素诱导的高血糖。这些研究表明，SRIF及其类似物可能在脑内发挥作用以影响糖调节。
